Who
Bethany J. Cavanagh
SVP, Finance and Treasurer
Company insider
Files Form 4 as: SVP, Finance and Treasurer, Beam Therapeutics.
In numbers
- Trades disclosed
- 20
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $1.1M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 31 Aug 2024
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $4,565187 at $24.41 | filing |
| 1 Apr 2026filed 6 Apr 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $80K3,242 at $24.58 | filing |
| 1 Apr 2026filed 6 Apr 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $80K3,242 at $24.58 | filing |
| 31 Mar 2026filed 2 Apr 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 31 Jan 2026filed 2 Feb 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 31 Jan 2026filed 2 Feb 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $217K6,198 at $35.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $217K6,198 at $35.00 | filing |
| 20 Jan 2026filed 21 Jan 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $91K3,034 at $30.12 | filing |
| 20 Jan 2026filed 21 Jan 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $91K3,034 at $30.12 | filing |
| 1 Oct 2025filed 3 Oct 2025 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $11K467 at $24.53 | filing |
| 1 Apr 2025filed 3 Apr 2025 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $55K3,015 at $18.35 | filing |
| 31 Mar 2025filed 2 Apr 2025 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 18 Feb 2025filed 20 Feb 2025 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $220K6,287 at $35.00 | filing |
| 31 Jan 2025filed 3 Feb 2025 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $28K1,117 at $24.68 | filing |
| 1 Oct 2024filed 2 Oct 2024 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $6,786289 at $23.48 | filing |
| 30 Sep 2024filed 2 Oct 2024 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 31 Aug 2024filed 3 Sep 2024 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
News
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?BEAM · fool.com · 18 Oct 2026Beam Therapeutics (NASDAQ: BEAM) CEO sells 50,000 shares after option exerciseBEAM · tickerreport.com · 17 Oct 2026Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual CongressBEAM · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Bethany J. Cavanagh; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.